Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NASDAQ COMPOSITE 2,169.47 -20.14 -0.92% not a good day so far
Any one home?
Webcast - Replay
ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society Of Hematology Meeting
12/08/09 at 8:30 a.m. ET
http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-calendar
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjU2NjA3N3xDaGlsZElEPTM2MTcyN3xUeXBlPTI=&t=1
12/7/09 Ariad Pharmaceuticals reports positive Phase 1 results on AP24534
http://investorshub.advfn.com/boards/post_new.aspx?board_id=2047
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
Business Wire
posted: 16 HOURS 23 MINUTES AGOARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers. The data provide strong clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutation of the target protein, BCR-ABL. The data are being presented this afternoon at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA.
The primary objectives of the Phase 1 study in patients with refractory hematological cancers are to determine a maximum tolerated dose and the recommended dose for further study of AP24534 and to examine its safety and antitumor activity. The trial uses an open-label, dose-escalating design.
Forty-four patients have been enrolled to date in the study in six dosing cohorts (2, 4, 8, 15, 30 and 60 mg administered orally once daily); 40 of the patients have resistant and refractory CML or Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). All of these 40 patients have been treated with, and were resistant to, the available first- and second-line targeted therapies for CML and, in most instances, with other investigational agents as well. Eighty-one percent of CML and Ph+ ALL patients in the study were resistant to at least three tyrosine kinase inhibitors, including imatinib (Gleevec®), dasatinib (Sprycel®), and nilotinib (Tasigna®).
“The initial findings from this study show AP24534 to be well-tolerated and to produce beneficial anti-leukemia activity in patients who have failed prior tyrosine kinase inhibitor therapy for CML,” stated Jorge Cortes, M.D., professor and deputy chair, Department of Leukemia, M.D. Anderson Cancer Center and the study’s principal investigator. “Pending further clinical trials, AP24534 appears to represent a potential significant advance for CML patients who have become resistant or refractory to currently available therapies and who are in great need of new treatment options.”
Key data from the study presented at ASH include:
Safety data show AP24534 to be well tolerated. There were no dose-limiting toxicities (DLTs) observed at dose levels lower than 60 mg.
Of the 44 patients treated with AP24534, 28 have chronic phase CML, 5 have accelerated phase CML, 5 have blast phase CML, 2 have Ph+ ALL and 4 have non-CML hematologic malignancies. Twenty-eight patients currently remain on study, with 22 at the three highest dose levels (15, 30 and 60 mg/day).
Of 20 chronic phase CML patients evaluable for cytogenetic response across all dose levels, 25 percent (5 of 20) demonstrated a complete cytogenetic response, 45 percent (9 of 20) experienced a major cytogenetic response, and 60 percent (12 of 20) demonstrated any cytogenetic response (i.e. major, minor or minimal response). One of four evaluable accelerated phase patients experienced a complete cytogenetic response. No response was seen in the seven blast phase or Ph+ ALL patients.
A complete hematologic response was observed in eighty-three percent (10 of 12) of chronic phase CML patients evaluable for hematologic response. An additional 10 chronic phase patients entered the study already meeting the criteria for CHR and were maintained. A major hematologic response was observed in three of four accelerated phase patients, none of five blast phase patients, and one of two Ph+ ALL patients.
In patients with resistant BCR-ABL mutations, hematologic, cytogenetic, and molecular responses have been observed. Of the 18 CML patients with the T315I mutation in the study, 55 percent (10 of 18) currently have chronic phase disease, and nine of these patients remain on study. Seven chronic phase patients are evaluable for response. Of them, all have achieved a complete hematologic response and 43 percent have experienced a major cytogenetic response.
Consistent with the pre-clinical profile of AP24534 as a pan-BCR-ABL inhibitor, responses also have been seen in patients with mutations other than T315I that confer resistance to either dasatinib or nilotinib. One patient with the F359C mutation, resistant to both imatinib and nilotinib, demonstrated a complete hematologic response, complete cytogenetic response and major molecular response after three months on 15 mg of AP24534. One other patient in the study with the F317L mutation, resistant to imatinib, dasatinib and nilotinib experienced a complete cytogenetic response after three months on 60 mg of AP24534.
There were four patients with DLTs out of 12 patients evaluable at the 60 mg dose level. The dose-limiting toxicities are chemical and clinical pancreatitis (i.e. elevated amylase and lipase, and grade 2 pancreatitis). The most common laboratory abnormalities have been mild to moderate thrombocytopenia (low platelet count) and neutropenia (low white blood cell count) which were found to be more common in patients with blast and accelerated phases of CML and Ph+ALL.
Pharmacokinetic data indicate that blood levels have been achieved that surpass those predicted preclinically to be associated with complete inhibition of all resistant mutants. Pharmacodynamic data demonstrate sustained target inhibition at doses of 8 mg and higher against a spectrum of BCR-ABL variants. These observations included evidence of sustained target inhibition against the T315I mutant observed at dose levels of 15 mg and above.
“These are remarkable results in heavily pre-treated patients with resistant leukemia that demonstrate hematologic, cytogenetic and molecular responses to AP24534,” said Frank G. Haluska, M.D., Ph.D., vice president, clinical affairs at ARIAD. “The data provide evidence of clinical proof-of-concept of AP24534 in patients who have very few, if any, viable treatment options available to them.”
“The confirmation of anti-tumor activity by AP24534 in this patient population is strong, even in the lower dose cohorts and in those patients who have received only short courses of therapy to date. We will complete enrollment in this study and undertake additional evaluation of the data in the coming months as we consult with regulatory agencies on beginning a pivotal registration trial of AP24534 in the second half of next year,” Dr. Haluska added.
Conference Call and Webcast Information
ARIAD will hold an investor conference call and webcast at 8:30 a.m. (ET) tomorrow, December 8, 2009 to discuss these data presented at ASH. ARIAD senior management and Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, M.D. Anderson Cancer Center will review and discuss the findings from this trial of AP24534. The webcast can be accessed by visiting the investor page of www.ariad.com and clicking on the link to the AP24534 presentation webcast. The call can be accessed by dialing 866-202-4683 (domestic) or 617-213-8846 (international) five minutes prior to the start time and providing the pass code 89813235. A replay of the webcast will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.
About CML and Ph+ ALL
CML is characterized by an excessive and unregulated production of white blood cells by the bone marrow due to a genetic abnormality that produces the BCR-ABL protein. After a chronic phase of production of too many white blood cells, CML typically evolves to more aggressive phases such as accelerated or blast crisis. Ph+ ALL is a subtype of acute lymphoblastic leukemia that also carries the Ph+ chromosome that produces BCR-ABL. It has a more aggressive course than CML and is often treated with a combination of chemotherapy and tyrosine kinase inhibitors. Because both of these diseases express the BCR-ABL protein, this would render them potentially susceptible to treatment with AP24534.
About ARIAD
ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD’s second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-?B cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.
This press release contains “forward-looking statements” including, but not limited to, statements relating to the updated clinical data for AP24534, continued enrollment in the Phase 1 clinical trial, the potential for data from this trial forming the basis for a pivotal registration trial of AP24534 and the timing of the start of such trial. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, preclinical data and early-stage clinical data that may not be replicated in later-stage clinical studies, the costs associated with our research, development, manufacturing and other activities, the conduct, timing and results of pre-clinical and clinical studies of our product candidates, the adequacy of our capital resources and the availability of additional funding, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
Gleevec® and Tasigna® are registered trademarks of Novartis AG, and Sprycel® is
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 7, 2009
ARIAD Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-21696
22-3106987
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
26 Landsdowne Street, Cambridge, Massachusetts
02139
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (617) 494-0400
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
ITEM 8.01
Other Events.
On December 7, 2009 ARIAD Pharmaceuticals, Inc. (the “Company”) issued a press release announcing positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers. The data provide strong clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutation of the target protein, BCR-ABL. The data are being presented on this day at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA.
A copy of the press release is being filed herewith as Exhibit 99.1 and this information contained therein is incorporated by reference into this Current Report on Form 8-K.
ITEM 9.01
Financial Statements and Exhibits
99.1 Press Release dated December 7, 2009.
2
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ARIAD Pharmaceuticals, Inc.
Date: December 7, 2009
By: /s/ Edward M. Fitzgerald
Edward M. Fitzgerald
Senior Vice President, Chief Financial Officer
Exhibit Index
Exhibit Number
Description
99.1 Press Release dated December 7, 2009.
Exhibit 99.1
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
~ First results of safety and clinical activity against broad spectrum of BCR-ABL mutations
~ Evidence of clinical anti-tumor activity in resistant and refractory patients
NEW ORLEANS--(BUSINESS WIRE)--December 7, 2009--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers. The data provide strong clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutation of the target protein, BCR-ABL. The data are being presented this afternoon at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA.
The primary objectives of the Phase 1 study in patients with refractory hematological cancers are to determine a maximum tolerated dose and the recommended dose for further study of AP24534 and to examine its safety and antitumor activity. The trial uses an open-label, dose-escalating design.
Forty-four patients have been enrolled to date in the study in six dosing cohorts (2, 4, 8, 15, 30 and 60 mg administered orally once daily); 40 of the patients have resistant and refractory CML or Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). All of these 40 patients have been treated with, and were resistant to, the available first- and second-line targeted therapies for CML and, in most instances, with other investigational agents as well. Eighty-one percent of CML and Ph+ ALL patients in the study were resistant to at least three tyrosine kinase inhibitors, including imatinib (Gleevec®), dasatinib (Sprycel®), and nilotinib (Tasigna®).
--------------------------------------------------------------------------------
“The initial findings from this study show AP24534 to be well-tolerated and to produce beneficial anti-leukemia activity in patients who have failed prior tyrosine kinase inhibitor therapy for CML,” stated Jorge Cortes, M.D., professor and deputy chair, Department of Leukemia, M.D. Anderson Cancer Center and the study’s principal investigator. “Pending further clinical trials, AP24534 appears to represent a potential significant advance for CML patients who have become resistant or refractory to currently available therapies and who are in great need of new treatment options.”
Key data from the study presented at ASH include:
Safety data show AP24534 to be well tolerated. There were no dose-limiting toxicities (DLTs) observed at dose levels lower than 60 mg.
Of the 44 patients treated with AP24534, 28 have chronic phase CML, 5 have accelerated phase CML, 5 have blast phase CML, 2 have Ph+ ALL and 4 have non-CML hematologic malignancies. Twenty-eight patients currently remain on study, with 22 at the three highest dose levels (15, 30 and 60 mg/day).
Of 20 chronic phase CML patients evaluable for cytogenetic response across all dose levels, 25 percent (5 of 20) demonstrated a complete cytogenetic response, 45 percent (9 of 20) experienced a major cytogenetic response, and 60 percent (12 of 20) demonstrated any cytogenetic response (i.e. major, minor or minimal response). One of four evaluable accelerated phase patients experienced a complete cytogenetic response. No response was seen in the seven blast phase or Ph+ ALL patients.
A complete hematologic response was observed in eighty-three percent (10 of 12) of chronic phase CML patients evaluable for hematologic response. An additional 10 chronic phase patients entered the study already meeting the criteria for CHR and were maintained. A major hematologic response was observed in three of four accelerated phase patients, none of five blast phase patients, and one of two Ph+ ALL patients.
In patients with resistant BCR-ABL mutations, hematologic, cytogenetic, and molecular responses have been observed. Of the 18 CML patients with the T315I mutation in the study, 55 percent (10 of 18) currently have chronic phase disease, and nine of these patients remain on study. Seven chronic phase patients are evaluable for response. Of them, all have achieved a complete hematologic response and 43 percent have experienced a major cytogenetic response.
Consistent with the pre-clinical profile of AP24534 as a pan-BCR-ABL inhibitor, responses also have been seen in patients with mutations other than T315I that confer resistance to either dasatinib or nilotinib. One patient with the F359C mutation, resistant to both imatinib and nilotinib, demonstrated a complete hematologic response, complete cytogenetic response and major molecular response after three months on 15 mg of AP24534. One other patient in the study with the F317L mutation, resistant to imatinib, dasatinib and nilotinib experienced a complete cytogenetic response after three months on 60 mg of AP24534.
There were four patients with DLTs out of 12 patients evaluable at the 60 mg dose level. The dose-limiting toxicities are chemical and clinical pancreatitis (i.e. elevated amylase and lipase, and grade 2 pancreatitis). The most common laboratory abnormalities have been mild to moderate thrombocytopenia (low platelet count) and neutropenia (low white blood cell count) which were found to be more common in patients with blast and accelerated phases of CML and Ph+ALL.
Pharmacokinetic data indicate that blood levels have been achieved that surpass those predicted preclinically to be associated with complete inhibition of all resistant mutants. Pharmacodynamic data demonstrate sustained target inhibition at doses of 8 mg and higher against a spectrum of BCR-ABL variants. These observations included evidence of sustained target inhibition against the T315I mutant observed at dose levels of 15 mg and above.
--------------------------------------------------------------------------------
“These are remarkable results in heavily pre-treated patients with resistant leukemia that demonstrate hematologic, cytogenetic and molecular responses to AP24534,” said Frank G. Haluska, M.D., Ph.D., vice president, clinical affairs at ARIAD. “The data provide evidence of clinical proof-of-concept of AP24534 in patients who have very few, if any, viable treatment options available to them.”
“The confirmation of anti-tumor activity by AP24534 in this patient population is strong, even in the lower dose cohorts and in those patients who have received only short courses of therapy to date. We will complete enrollment in this study and undertake additional evaluation of the data in the coming months as we consult with regulatory agencies on beginning a pivotal registration trial of AP24534 in the second half of next year,” Dr. Haluska added.
Conference Call and Webcast Information
ARIAD will hold an investor conference call and webcast at 8:30 a.m. (ET) tomorrow, December 8, 2009 to discuss these data presented at ASH. ARIAD senior management and Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, M.D. Anderson Cancer Center will review and discuss the findings from this trial of AP24534. The webcast can be accessed by visiting the investor page of www.ariad.com and clicking on the link to the AP24534 presentation webcast. The call can be accessed by dialing 866-202-4683 (domestic) or 617-213-8846 (international) five minutes prior to the start time and providing the pass code 89813235. A replay of the webcast will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.
About CML and Ph+ ALL
CML is characterized by an excessive and unregulated production of white blood cells by the bone marrow due to a genetic abnormality that produces the BCR-ABL protein. After a chronic phase of production of too many white blood cells, CML typically evolves to more aggressive phases such as accelerated or blast crisis. Ph+ ALL is a subtype of acute lymphoblastic leukemia that also carries the Ph+ chromosome that produces BCR-ABL. It has a more aggressive course than CML and is often treated with a combination of chemotherapy and tyrosine kinase inhibitors. Because both of these diseases express the BCR-ABL protein, this would render them potentially susceptible to treatment with AP24534.
About ARIAD
ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD’s second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-?B cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.
This press release contains “forward-looking statements” including, but not limited to, statements relating to the updated clinical data for AP24534, continued enrollment in the Phase 1 clinical trial, the potential for data from this trial forming the basis for a pivotal registration trial of AP24534 and the timing of the start of such trial. Forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, preclinical data and early-stage clinical data that may not be replicated in later-stage clinical studies, the costs associated with our research, development, manufacturing and other activities, the conduct, timing and results of pre-clinical and clinical studies of our product candidates, the adequacy of our capital resources and the availability of additional funding, and other factors detailed in the Company's public filings with the U.S. Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company's expectations, except as required by law.
Gleevec® and Tasigna® are registered trademarks of Novartis AG, and Sprycel® is a registered trademark of Bristol-Myers Squibb, Inc.
CONTACT:
ARIAD Pharmaceuticals, Inc.
Maria E. Cantor, 617-621-2208
File Name Filing Type Form Type Sequence
091226894.htm ARIAD PHARMACEUTICALS, INC. 8-K 8-K 1
0001157523-09-008469a6115050ex991.htm EXHIBIT 99.1 EX-99.1 2
:32 EDT ARIA theflyonthewall.com: Ariad Pharmaceuticals reports positive Phase 1 results on AP24534
Ariad Pharmaceuticals announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers. The data provide strong clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia, including those with the T315I mutation of the target protein, BCR-ABL. The data are being presented at the 51st Annual Meeting of the American Society of Hematology being held in New Orleans, LA. :theflyonthewall.com
News For ARIA From The Last 14 Days
Check below for free stories on ARIA the last two weeks.
There are 2 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
December 7, 2009
17:32 EDT ARIA theflyonthewall.com: Ariad Pharmaceuticals reports positive Phase 1 results on AP24534
Subscribe for More Information :theflyonthewall.com
December 3, 2009
16:52 EDT ARIA theflyonthewall.com: Ariad Pharmaceuticals to host a conference call
Conference call to review and discuss the findings from Phase I Trial of Oral AP-24534 which were presented at the American Society of Hematology (ASH) 51st Annual Meeting will be held on December 8 at 11:30 am. Webcast Link :theflyonthewall.com
.0028 X4
What “mwwarner1 thought smelled like an Ass” here is the stench that comes from the disgusting odor the MM leave with all the ones that they legally pick pocket as they play us with there underhanded ways like rs99 said “MMs just running this down to trip trade triggers and getting people to panic sell”. It should be illegal but I guess it’s not. So we are along for the ride, and hope the MM’s don’t tinker with the stock so much they destroy all confidence in it!
Does anyone have a way to show total numbers of stock publicly owned, company owned and 3rd patty owned and shorted?
Anyone got a ROPE?
Who are these JURKS that keep running this stock down at the close when it worked its way up all day?????????????????????????
That’s because the MMs screwed with the health of the stock by there manipulation so many times that there running investors off who also will make warnings to others as they blog on other sites. So Mr. D & the MMs are shooting themselves and us in the foot!
That’s because the MMs screwed with the health of the stock by there manipulation so many times that there running investors off who also will make warnings to others as they blog on other sites. So Mr. D & the MMs are shooting themselves and us in the foot!
I have a buy in @ .0023 –its not filling!! Wait—just filled took some time
I have a buy in @ .0023 –its not filling!! Wait—just filled took some time
I have a buy in @ .0023 –its not filling!!
It would seem logical BZCN will media blitz soon, they still wont the eBay business $$$ ALSO
In this world of emotions that sometimes go postal, I hope MD has his back covered! For the rest of us we need to work with the Yo-Yo instead of being the Yo-Yo. We have 22 days of shopping ( 19 with shipping). This stocks rhythm can be seen in its daily/weekly swings; but in the end the Mighty SHOPPER” $$ is going to pull the price up !
Wish I had more $$$--- at this price I would scup up a boatload more!! This is a buy price!!!!
Wish I had more $$$--- at this price I would scup up more!!
If you consider where some came in month or so back and loaded up piles cheap, I did but sold and took a walk to soon, but those that didn’t have a boatload to take off the table and its all $$$$. Could be part of the selling
I’ll take a chill pill~ it will just take some time to get its lags.
Who are the puppeteers pulling our strings? This is nuts, eBay is cooking, if BZCN business model is sound and the c-cards are jingling WHAT the problem?
Are the false gods of BZCN manipulating us again, demanding more sacrifices from us? Is there no way to tare down there temples and smash there graven images?
I think we just suffered a fickled opening with to high a price and the ones holding huge numbers of low priced stock couldn’t resist taking some of the table. Now everyone is skittish!
Who’s game is this????
I just got back in. I balled a will back (large tears) had nice size of shares, spilt milk! A question, did the controllers that dumped and dumped shares run out of shares to dump?
Who is selling @.0043 .0044??????? --- are they trying to run the price down??
Maybe when it starts to move up and it will hopefully, this site will liven up!
I want you to be wrong to, but I don’t think your are!
Maybe .00000
I Bought EVFL @ 0.0002 & 0.0003 in early July on hip and finally sold 9-16 @ 0.0001 feeling this stock will likely fall more with all the manipulation on going. Sorry, I still feel that way and was wonder if most feel there in to high to sell and are just hopping, or truly think it will go up?
Is something really happening today or is it same-o-samo?
Please and I ask this sincerely, what keeps this board going, can anyone explain? I sold on 9-16 @ 0.0001 (just got tired of it). It’s been flat lined at that from mid August tell now. What news or rational have I missed that holds you together? Is there still an endless supply of stock selling at bottom feeding prices and the few times it hit 0.0002 could anyone get a sale through? I just stopped to check this stock and am curious. Thanks
This message board for ARIA is like an abandoned truck stop, it’s been deserted. I appreciate your post and hopefully you’ll check back to see this. I think this stock will bring good retunes as it contuse to develop it's formulas and I also like being associated with a company developing cures for cancer. I’ve been on other I-Hub boards where it’s full of activity. Where’s the interest here?
Maybe a mistake, but I out with a small loss. I may cry if it goes up & up; hope for you it will. Just more frustration by MMs & company’s bottomless bucket of stock to dump at low $$ then I want to deal with
If we stopped buying all these “Available shares to sell at low levels that seems to be unlimited”. Really stop handing $$$ to the MMs or use as much influence as we can muster to slow trading would that psych the MMs to show some respect to the value that stockholders need to stay in the game?
WHERE DID YOU GET THAT INFO? “MMs selling small blocks”
ARIAD to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Business Wire
posted: 2 HOURS 16 MINUTES AGOARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it is scheduled to present at the Lazard Capital Markets 6th Annual Healthcare Conference being held at the St. Regis Hotel in New York City, New York. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, is scheduled to provide an overview of the Company and its progress in key programs in a corporate presentation on Tuesday, November 17 at 11:25 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at http://www.ariad.com/investor. A replay of the presentation will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for four weeks.
ARIAD to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Last update: 11/10/2009 7:35:02 AM
CAMBRIDGE, Mass., Nov 10, 2009 (BUSINESS WIRE) -- ARIAD Pharmaceuticals, Inc. (ARIA) today announced that it is scheduled to present at the Lazard Capital Markets 6th Annual Healthcare Conference being held at the St. Regis Hotel in New York City, New York. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, is scheduled to provide an overview of the Company and its progress in key programs in a corporate presentation on Tuesday, November 17 at 11:25 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at . A replay of the presentation will be available on the ARIAD website approximately twenty-four hours after the presentation and will be archived for four weeks.